SILO PHARMA INC (SILO)
US82711P2011 - Common Stock
Taking everything into account, SILO scores 3 out of 10 in our fundamental rating. SILO was compared to 565 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SILO as it has an excellent financial health rating, but there are worries on the profitability. SILO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
SILO had negative earnings in the past year.
SILO had a negative operating cash flow in the past year.
In the past 5 years SILO reported 4 times negative net income.
In the past 5 years SILO always reported negative operating cash flow.
1.2 Ratios
SILO has a Return On Assets of -44.16%. This is comparable to the rest of the industry: SILO outperforms 52.31% of its industry peers.
Looking at the Return On Equity, with a value of -55.78%, SILO is in the better half of the industry, outperforming 63.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.16% | ||
| ROE | -55.78% | ||
| ROIC | N/A |
ROA(3y)-19.18%
ROA(5y)-96.23%
ROE(3y)-23.38%
ROE(5y)-115.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 91.90%, SILO belongs to the top of the industry, outperforming 93.95% of the companies in the same industry.
SILO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for SILO has been reduced compared to 1 year ago.
The number of shares outstanding for SILO has been increased compared to 5 years ago.
There is no outstanding debt for SILO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -1.31, we must say that SILO is in the distress zone and has some risk of bankruptcy.
SILO has a Altman-Z score (-1.31) which is comparable to the rest of the industry.
SILO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.31 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
SILO has a Current Ratio of 7.91. This indicates that SILO is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.91, SILO is doing good in the industry, outperforming 72.24% of the companies in the same industry.
A Quick Ratio of 7.91 indicates that SILO has no problem at all paying its short term obligations.
SILO has a Quick ratio of 7.91. This is in the better half of the industry: SILO outperforms 72.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.91 | ||
| Quick Ratio | 7.91 |
3. Growth
3.1 Past
SILO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.88%, which is quite good.
SILO shows a decrease in Revenue. In the last year, the revenue decreased by -9.85%.
EPS 1Y (TTM)11.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.81%
Revenue 1Y (TTM)-9.85%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-9.85%
3.2 Future
SILO is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.48% yearly.
Based on estimates for the next years, SILO will show a decrease in Revenue. The Revenue will decrease by 0.00% on average per year.
EPS Next Y45.1%
EPS Next 2Y14.62%
EPS Next 3Y8.97%
EPS Next 5Y-3.48%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y0%
Revenue Next 5Y0%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
SILO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SILO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.62%
EPS Next 3Y8.97%
5. Dividend
5.1 Amount
No dividends for SILO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SILO PHARMA INC
NASDAQ:SILO (12/24/2024, 7:37:49 PM)
After market: 0.9401 -0.02 (-1.93%)0.9586
+0.08 (+8.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.67%
Inst Owner Change182.5%
Ins Owners4.14%
Ins Owner Change3.89%
Market Cap4.29M
Analysts82.86
Price Target10.2 (964.05%)
Short Float %3.97%
Short Ratio0.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 59.55 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.63 | ||
| P/tB | 0.66 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.18
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS0.02
BVpS1.51
TBVpS1.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.16% | ||
| ROE | -55.78% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.9% | ||
| FCFM | N/A |
ROA(3y)-19.18%
ROA(5y)-96.23%
ROE(3y)-23.38%
ROE(5y)-115.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.91 | ||
| Quick Ratio | 7.91 | ||
| Altman-Z | -1.31 |
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.81%
EPS Next Y45.1%
EPS Next 2Y14.62%
EPS Next 3Y8.97%
EPS Next 5Y-3.48%
Revenue 1Y (TTM)-9.85%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-9.85%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y0%
Revenue Next 5Y0%
EBIT growth 1Y6.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-13.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.01%
OCF growth 3YN/A
OCF growth 5YN/A